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AbstrAct
background The interference in the immune response 
induced by biological disease-modifying antirheumatic 
drugs (bDMARDs) increases the risk of reactivation of 
infections. Treatment of patients with chronic hepatitis 
C virus (HCV) infection and psoriasis is complex. The 
efficacy and safety of the new direct-acting antiviral 
agents (DAA) when combined with bDMARDs remain 
unknown.
case report We present a case of a 44-year-old 
Caucasian man affected with psoriasis and HCV 
infection. Throughout the course of the psoriatic disease, 
this patient received several lines of treatment, including 
secukinumab, a new type of bDMARD. At the time of 
commencing secukinumab, new DAA agents (ledipasvir/
sofosbuvir) were also initiated. At week 12 post-
treatment, hepatitis C viral load was undetectable and 
the patient remained in remission of psoriasis.
conclusion This case report suggests that secukinumab 
is a therapeutic option in patients with psoriasis, 
particularly in those cases with HCV infection where 
treatment with DAA agents is warranted.
bAckground
Psoriasis is an immunologically driven chronic 
inflammatory condition which is mainly cuta-
neous and in which genetic predisposition plays 
an important role.1 The choice of therapy depends 
on the severity of the cutaneous symptoms; this is 
generally measured using the Psoriasis Area and 
Severity Index (PASI) score. The first line of treat-
ment consists of topical drugs: emollients, vitamin 
D analogues or corticosteroids either alone or in 
combination with ultraviolet light.2 3 Systemic 
therapy with retinoids or immunosuppressive drug-
slike methotrexate or cyclosporine is indicated in 
patients not responding to topical medication.4
In the last decade, the introduction of biological 
disease-modifying antirheumatic drugs (bDMARDs) 
has completely revolutionised systemic manage-
ment of severe psoriasis due to significant decreases 
in the number of hospital stays, reduction in use 
of other systemic therapies and increased patient 
satisfaction.5 Infliximab, etanercept and adalim-
umab (anti-tumour necrosis factor-α; anti-TNF-α), 
which block the activity of TNF-α (anti-TNF-α), 
were the first bDMARDs used. Later came usteki-
numab, a human IgG1 monoclonal antibody, which 
binds with specificity to the p40 protein subunit, 
used by both the interleukin (IL)-12 and IL-23 
cytokines. Secukinumab has been the latest addi-
tion to the group and is a first-in-class fully human 
monoclonal antibody which selectively binds and 
neutralises the proinflammatory cytokine IL-17A; 
this is a more specific mechanism of action for 
fighting psoriasis, as it upregulates keratinocyte 
chemokines.6
The interference in the immune response induced 
by bDMARDs, particularly with anti-TNF-α agents, 
increases the risk of reactivation of different infec-
tions.7 Therefore, it is important to adequately 
screen for several chronic infectious diseases before 
bDMARDs therapy is initiated.7 Chronic hepatitis 
C virus (HCV) infection is particularly problematic 
as different studies have shown a higher prevalence 
of this infection in patients with psoriasis, an asso-
ciation which is unrelated to previous exposure to 
interferon, already known to induce or exacerbate 
psoriasis.8 9
Treatment of patients with psoriasis and chronic 
HCV infection is complex. The benefits of 
bDMARDs controlling the psoriasis activity need to 
be balanced against the risk of inducing an increased 
replication of HCV.10 In a series of retrospective 
studies, the use of anti-TNF-α11 12 13 or usteki-
numab14 was not associated with an increase in the 
viral load in the majority of patients with HCV.
On the other hand, drug treatments for hepa-
titis C infections have advanced greatly in the last 
few years with a move away from interferon-based 
treatments to a new generation of direct-acting 
antiviral agents (DAA). Different DAA drugs such 
as sofosbuvir, simeprevir and daclatasvir as well 
as combinations, for example, ombitasvir–parita-
previr–ritonavir–dasabuvir and sofosbuvir–ledi-
pasvir were then available.15 16 The efficacy and 
safety of these new interferon (IFN)-free antiviral 
treatments when combined with bDMARDs remain 
unknown.10
cAse presentAtion
 We report a patient with HCV infection receiving 
secukinumab, the newest bDMARD for the treat-
ment of psoriasis. The impact of secukinumab on 
liver function and the potential interactions with 
DAA are discussed.
The patient was a 44-year-old Caucasian man 
with plaque-type psoriasis; he was attending our 
dermatology outpatient unit. He was an ex-par-
enteral drug user with a medical history of HCV 
infection, genotypes 3a and 4, diagnosed in 1997. 
He referred no significant alcohol use.
Psoriasis was diagnosed in 2003 and, given the 
severity of the cutaneous involvement (PASI score 
of 9), the patient was prescribed topical corticoste-
roids and emollients combined with oral cyclospo-
rine at a dose of 150 mg/day. He continued to be 
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stable for 5 years, complying with the treatment and attending 
regular check-ups.
In January 2008, the patient was found to meet criteria to 
initiate antiviral HCV therapy. Laboratory analysis revealed 
the following results: alanine aminotransferase (ALT) 34 UI/L, 
aspartate aminotransferase (AST) 49 UI/L, gamma-glutamyl 
transpeptidase (GGT) 36 UI/L and HCV PCR 15 500 000 IU/
mL (7.19log UI/mL). A fibroscan estimated the degree of liver 
fibrosis to be F0–F1. The physician responsible for his care 
discussed the treatment options with the patient and proposed 
commencing pegylated-interferon/ribavirin (peg-IFN/rib), 
which would be added to the psoriasis treatment. In consul-
tation with the outpatient pharmacist, the patient was given 
recommendations on importance of adherence to treatment, 
medication administration, possible interactions and side 
effects. After careful consideration, the patient and the multi-
disciplinary team involved in his care decided that the risk of 
peg-INF worsening his dermatological condition outweighed 
the possible benefits from treatment. As a result, the patient 
declined antiviral therapy.
In November 2008, the initial psoriasis treatment based on the 
administration of topical corticosteroids, emollients and systemic 
cyclosporine proved to be insufficient for adequate control of the 
disease. Therapy needed to be stepped up to a biological agent. 
The corresponding consultant and pharmacist reviewed which 
would be the biological agent of choice for this case taking into 
consideration the type of psoriasis, information about previous 
treatments, contraindications, precautions and current guide-
lines, and a treatment request form for subcutaneous etanercept 
was completed and approved by a panel. Before starting therapy 
with etanercept, prophylactic isoniazid 300 mg/day was given 
for a month (which then continued for a further 9 months) as the 
patient was diagnosed as having a latent tuberculosis infection. 
Etanercept was initiated at 50 mg every fortnight, given concom-
itantly with a weaning dose of prednisone. The patient attended 
the outpatient pharmacy department for treatment initiation and 
during consultation with the dispensing pharmacist he received 
education on administration, possible side effects, storage condi-
tions and counselling on how to proceed in the event of missed 
doses.
Following the first two doses of etanercept, the patient rang 
the pharmacy department for advice as he was experiencing 
generalised pruritus and hand and feet oedemas. The patient was 
referred to urgent care, where he was treated with ibuprofen 
and dexclorfeniramina. Treatment was, therefore, switched to 
subcutaneous adalimumab 40 mg every 2 weeks, after a new 
discussion of the case between the pharmacy and dermatology 
departments. The patient attended the pharmacy outpatient 
department for adalimumab initiation and then on a monthly 
basis for treatment monitoring (including PASI and acute phase 
reactants). The patient responded well, reaching PASI scores 
of 0–2 after 1 year of treatment, and continued to show stable 
psoriatic disease for a further 3-year period. No remarkable 
complications arose while the patient was receiving adalimumab.
After this uneventful 4-year period of treatment with adalim-
umab, the disease flared up again with a PASI score of 5–6. Doses 
were increased to 40 mg weekly and the disease remained under 
control for an additional 3-year period. In September 2015, after 
7 years of treatment with adalimumab, the patient presented 
a severe exacerbation with a PASI score of 32. Consequently, 
adalimumab was interrupted and treatment was switched to 
secukinumab. Based on the half-life of adalimumab, a 4-week 
washout period was suggested by the specialist pharmacist, and 
after this period, secukinumab was initiated at a loading dose of 
300 mg weekly for 4 weeks followed by a maintenance dose of 
300 mg every 4 weeks from there on.
During the washout period between adalimumab and secuki-
numab, the patient attended a follow-up visit with the liver disease 
specialist. Liver fibrosis, measured by fibroscan, had progressed 
to F4 degree and laboratory analysis yielded the following 
values: ALT 56 UI/L, AST 46 UI/L, GGT 35 UI/L and HCV PCR 
15 500 000 IU/mL (7.19log UI/mL). At this point in time, new 
drug treatments for hepatitis C infections had been made avail-
able. These newer, oral, direct-acting drugs are more effective, 
have fewer side-effects, are easier to take and are less debilitating 
for patients. A revision of the latest European and Spanish guide-
lines15 16 17 was conducted by the infectious diseases specialist 
pharmacist and this revision was then discussed with the physi-
cian and presented at the multidisciplinary committee where it 
was decided that the optimum regimen for this particular viral 
genotype would be a combination of ledipasvir/sofosbuvir and 
ribavirin. Therapy with ledipasvir 90 mg/sofosbuvir 400 mg and 
ribavirin capsules 200 mg (2–0–3) daily for 12 weeks was initi-
ated 18 days before starting secukinumab. Figure 1 shows the 
course of PASI score and liver function in relation to drug intake.
investigAtions
The effect of biological therapy on reactivation of HCV is 
at present unknown and is very much in debate.10 This is an 
important issue due to the higher frequency of HCV infection in 
patients with psoriasis who may have indication for bDMARDs.
There is published evidence on the safe use of anti-TNF-α and 
ustekinumab in patients infected with HCV who are undergoing 
treatment with peg-INF and ribavirin.11 12 14 18 However, there 
is no data published to date in relation to the use of new DAA 
and other biological agents not targeting TNF-α, such as secuk-
inumab. To our knowledge, this is the first case published in the 
corresponding literature.
Prior to the beginning of the treatment for this patient, a 
medicines information enquiry was directed to the manufac-
turer (Gilead Labs) by the pharmacy department requesting 
information on the concomitant use of the association 
of ledipasvir–sofosbuvir plus ribavirin and secukinumab in 
this population of patients and particularly regarding the 
risk of increasing replication of HCV. A report was obtained 
confirming that pharmacological or pharmacokinetic interac-
tions were not expected, taking into account the drug's mech-
anism of action and the metabolic pathways used by these 
molecules.
treAtment
Choice of therapy for psoriasis after failure to adalimumab was 
decided taking into account two factors: previous lines of treat-
ment and maximum PASI values reached during the different 
previous therapies. It has been reported that anti-TNF efficacy 
decreases with time and the number of anti-TNF treatments 
received. This is due to antibody production against these mole-
cules. Consequently, it is recommended to switch to a different 
treatment option with a different therapeutic target in those 
patients that have received two previous lines of treatment with 
anti-TNF molecules, which was our patient’s case.19 A switch 
in the therapeutic target was suggested and ustekinumab or 
secukinumab was the two options available. At that time (March 
2016), our hospital protocol for treatment of moderate to severe 
psoriasis was updated. In this version of the protocol, a treat-
ment decision algorithm was established, and secukinumab was 
positioned as the biological drug of choice for the treatment of 
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psoriasis vulgaris with PASI ≥20, based on the results of two 
studies: FEATURE20 and JUNCTURE.21
Therefore, secukinumab was chosen and before initiation, the 
patient was seen in consultation by the dermatology/rheumatology 
specialist pharmacist who reviewed the patient’s medical records 
to verify that there was no medical history of infectious disease, 
explained treatment to the patient and clarified how future moni-
toring appointments would be scheduled. During treatment with 
secukinumab, the patient attended the pharmacy consultation room 
monthly for monitoring of treatment efficacy and safety.
As for the treatment for HCV, it was approved according to the 
guidelines outlined by AEEH (Spanish Liver Society): ‘II consensus 
document on hepatitis C treatment’.15 This document is in line 
with the National Strategic Plan for treatment of HCV which 
was approved by the Spanish National Health System in March 
2015 and the recommendations of the European Association for 
the Study of the Liver.16 After review of these guidelines, it was 
decided that first-line therapy for a patient showing genotype 3 
and 4 and F4 degree fibrosis was ledipasvir/sofosbuvir one tablet 
OD for 12 weeks. At present, these guidelines have been updated 
and this treatment option is no longer first line. Newer guidelines 
have now been published: ‘Guidelines AEEH/SEIMC for hepatitis 
C treatment’, edited in 2016 in collaboration with SEIMC (Spanish 
Society of Clinical Microbiology and Infectious Diseases).17 In 
consultation with the infectious disease (ID) specialist pharmacist, 
chronic medication taken by the patient was checked for interac-
tions before initiation of new treatment, posology and possible side 
effects were explained and further follow-up visits were scheduled 
for monitoring, in order to maximise efficacy and safety of treat-
ment. A multidisciplinary approach is key for success in treatment, 
and at this point, the ID specialist pharmacist and the dermatology/
rheumatology specialist pharmacist were working together and in 
collaboration with the multidisciplinary team to provide the best 
pharmaceutical care to their patient
outcome And follow-up
At week 4 of DAA treatment (January 2016), hepatitis C viral 
load was less than 15 IU/mL (1.16log UI/mL) and analytical liver 
parameters were: ALT 30 UI/L, AST 23 UI/L and GGT 21 UI/L. 
The patient complained of some minor degree of dizziness and 
pain. At this stage, the psoriasis had completely subsided with a 
PASI score of 0.
At week 12 (March 2016), hepatitis C viral load was still under 
15 UI/mL (1.16log UI/mL) and clinical parameters read: ALT/
figure 1. Schematic representation of the course of the liver function and PASI score in relation to drug intake. AST, aspartate aminotransferase; PASI, 
Psoriasis Area and Severity Index.
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AST=34/25, GGT=21. At week 12 post-treatment (June 2016), 
viral load was undetectable and analytical parameters were 
stable at ALT 30 UI/L, AST 23 UI/L and GGT 21 UI/L, meaning 
sustained viral response was achieved. Regarding psoriasis, the 
patient remains with a PASI score of 0 to date (September 2016).
discussion
A review of available literature was undertaken with the terms 
‘hepatitis C AND psoriasis’. As a result, isolated case reports and 
two systematic reviews (Pompili et al12 and Brunasso et al11) were 
listed. Pompili et al12 researched the use of anti-TNF-α in patients 
with HCV concluding that TNF-α has a minimal influence in HCV 
replication. These findings were the result of the analysis of small 
retrospective cohort studies and case reports. Of the 216 patients 
included, three abandoned treatment because of a worsening of 
their liver disease; however, these negative outcomes could not be 
attributed to concomitant biological treatment. In all other 213 
patients, the viral load was stable or had diminished.
Brunasso et al11 also conducted a systematic review on the use 
of anti-TNF-α in patients diagnosed with HCV infection. Their 
conclusions were very similar to those reached by Pompili et al. 
Patients treated concomitantly with anti-TNF-α and INF-riba-
virin showed improvement of their liver disease.
On another note, there are two studies showing controver-
sial information on the use of ustekinumab in this population 
of HCV infected patients. Chiu et al18 published a series of four 
cases where patients had a diagnosis of HCV infection and they 
had initiated treatment with ustekinumab, but they were not on 
active treatment with antivirals. Viral load increased in three out 
of those four cases. On the contrary, the three cases followed by 
Navarro et al14 showed no worsening of the liver disease.
It is well established that the presence of HCV is not a contra-
indication to therapy with TNF-α inhibitors, except in cirrhotic 
patients, in whom the benefit:risk ratio should be individually 
evaluated before treatment initiation.12 Moreover, the Spanish 
Society of Rheumatology outlines recommendations for moni-
toring treatment in this population of patients in the ‘Guideline 
for risk management in prescribing biological therapies’, where 
it is stated that anti-HCV antibody titres should be measured at 
initiation of treatment and, in case of positive result, continue 
to be monitored closely throughout.7 However, the presentation 
of this case to our day clinic raised a new question: would the 
biological agent affect the antiviral effect of DAA? The favour-
able outcomes of HCV infection and psoriasis seen in our patient 
suggest that secukinumab is a safe treatment in patients receiving 
DAA such as ledipasvir–sofosbuvir.
In conclusion, the presence of HCV infection under treat-
ment is not a contraindication for initiating a biological agent to 
treat psoriasis. Both evaluation of each individual case and close 
monitoring, carried out by a multidisciplinary team, are strongly 
recommended.
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learning points
 ► The efficacy and safety of the new direct-acting antiviral 
agents, when combined with biological agents, remain largely 
unknown.
 ► This case shows that the presence of hepatitis C virus 
infection under treatment is not a contraindication for 
initiating a biological agent.
 ► Evaluation of each individual case is necessary.
 ► Close monitoring by a multidisciplinary team during 
treatment is strongly recommended.
